The Medicines Co. v. Mylan Inc., No. 11 C 1285, Slip Op. (N.D. Ill. Oct. 30, 2017) (St. Eve, J.).

Judge St. Eve granted in part defendants’ bill of costs awarding $217k in this ANDA patent dispute.

Defendants were the prevailing party because they were determined not to infringe either of plaintiff’s patents. In

Apotex, Inc. v. Daiichi Sankyo, Inc., No. 12 C 9295 & 15 C 3695, Slip Op. (N.D. Ill. Jan. 8, 2016) (Coleman, J.).

Judge Coleman granted plaintiff Apotex’s motion for summary judgment of noninfringement in this ANDA patent case seeking to manufacture and sell generic version of Benicar and Benicar HCT.

As an initial

Cumberland Pharms., Inc. v. Mylan Institutional LLC, No. 12 C 3846, Slip Op. (N.D. Ill. Oct. 2, 2015) (Pallmeyer, J.).

Judge Pallmeyer, after a bench trial, found that defendants (collectively “Mylan”) had not met their burden of proving plaintiff Cumberland’s ‘445 patent – to an intravenous treatment for suspected acetaminophen overdoses – was invalid

Cumberland Pharms, Inc. v. Mylan Inst. LLC, No. 12 C 3846, Slip Op. (N.D. Ill. Feb. 26, 2014) (Pallmeyer, J.).

Judge Pallmeyer construed the claims in this patent infringement case involving an IV form N-acetylcysteine — used for treating acetaminophen overdoses.  Of particular note, the Court held as follows:

  • “Free From A Chelating Agent

The Medicines Co. v. Mylan, Inc., No. 11 C 1285, Slip Op. (N.D. Ill. June 13, 2013) (St. Eve, J.).

Judge St. Eve denied plaintiff The Medicines Company’s (“TMC”) motion to compel discovery withheld as privileged in this patent dispute.  Initially, the Court held that TMC failed to comply with Local Rule 37.2 by

The Medicines Co. v. Mylan Inc., No. 11 C 1285, Slip Op. (N.D. Ill. Aug. 6, 2012) (St. Eve, J.).

 Judge St. Eve construed the claims in this patent case related to bivalirudin.  Of particular note:

  • “Pharmaceutical Batches” was construed as “may include a single batch, wherein the single batch is representative of all